

Product datasheet for **KN408444**

HRAS like suppressor (HRASLS) Human Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	HRAS like suppressor
Locus ID:	57110



Components:

KN408444G1, HRAS like suppressor gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)
KN408444G2, HRAS like suppressor gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)
KN408444D, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA CATCGCCAC
AGTCCCCGAG AAGTTGGGGG GAGGGGTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG CGGGGTAAC TGGGAAAGTG
ATGTCGTGTA CTGGCTCCGC CTTTTTCCCG AGGGTGGGGG AGAACCGTAT ATAAGTCGAG TAGTCGCCGT GAACGTTCTT
TTTCGCAACG GGTTCGCGC CAGAACACAG GTAAGTGCCG TGTGTGGTTC CCGCGGGCCT GGCCTCTTTA CGGGTTATGG
CCCTTGCGTG CTTGAATTA CTTCCACCTG GCTGCAGTAC GTGATTCTTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG
AGAGTTCGAG GCCTTGCGCT TAAGGAGCCC CTTCGCCTCG TGCTTGAGTT GAGGCTGGC CTGGGCGCTG GGGCCGCCG
GTGCGAATCT GGTGGCACCT TCGCGCTGT CTCGCTGCT TCGATAAGTC TCTAGCCATT TAAATTTTTT GATGACCTGC
TGCGACGCTT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT TTTGGGGCCG
CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTT GGCGAGGCGG GGCTGCGAG CGCGGCCACC GAGAATCGGA
CGGGGTAGT CTAAGCTGG CCGGCTGCT CTGGTGCCTG GCCTCGCGCC GCCGTGTATC GCGCCGCCCT GGGCGGCAAG
GCTGGCCCGG TCGGCACCAG TTGCGTGAGC GGAAGATGG CCGCTCCCG GCCCTGCTGC AGGGAGCTCA AAATGGAGGA
CGCGGCGCTC GGGAGAGCGG GCGGGTGAGT CACCCACACA AAGGAAAAGG GCCTTTCGT CCTCAGCGCT CGCTTCATGT
GACTCCACGG AGTACCGGGC GCCGTCCAGG CACCTCGATT AGTTCGCG CTTTTGGAGT ACCTCGTCTT TAGGTTGGGG
GGAGGGGTTT TATGCGATGG AGTTTCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGGCAC TTGATGTAAT
TCTCCTTGA ATTTGCCCTT TTTGAGTTG GATCTTGTT CATTCTCAAG CTCAGACAG TGGTTCAAAG TTTTTTCTT
CCATTTACAG TGTCTGAAT GGAGAGCGAC GAGAGCGGCG TGCCCGCCAT GGAGATCGAG TGCCGCATCA CCGGCACCTC
GAACGCGCTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGCG ACCCCGAGC AGGGCCGCAT GACCAACAAG ATGAAGAGCA
CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA CGTGATGGG TACGGCTTCT ACCACTTCGG CACTACCCC
AGCGGCTACG AGAACCCCTT CCTGCACGCC ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG
CGGCGTGCTG CACGTGAGCT TCAGCTACCG CTACGAGGCC GGCCGCGTGA TCGCGCACTT CAAGGTGATG GGCACCGGCT
TCCCCGAGGA CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGGCGAT
AACGATCTGG ATGGCAGCTT CACCCGCACC TTCAGCCTGC GCGACGGCGG CTAACAGC TCCGTGGTGG ACAGCCACAT
GCATTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCCA TGTTGCCTT CCGCCGCGTG GAGGAGGATC
ACAGCAACAC CGAGCTGGG ATCGTGAGT ACCAGCACGC CTTCAGACC CCGGATGAG ATGCCGGTGA AGAAAGAGGA
AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGCC
CACGGTGCGC CTCGCCACCC GCGACGAGT CCCCAGGGCC GTACGCACCC TCGCCGCGCG GTTCGCCGAC TACCCGCCA
CGCGCCACAC CGTCGATCCG GACCGCCACA TCGAGCGGT CACCGAGCTG CAAGAACTCT TCCTCACGCG CGTCGGGCTC
GACATCGGCA AGGTGTGGT CGCGGACGAC GCGCGCGCGG TGCGGTCTG GACCACGCCG GAGAGCGTCG AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGCCG TGCGCGCGCA GCAACAGATG GAAGGCCTCC
TGGCGCCGCA CCGGCCAAG GAGCCCGCT GGTTCCTGCG CACCGTCGCG GTCTCGCCCG ACCACAGGG CAAGGGTCTG
GGCAGCGCCG TCGTGCTCCC CGGAGTGGAG GCGGCGGAG GCGCGGGGT GCCCGCTTC CTGGAGACCT CCGCGCCCCG
CAACCTCCCC TTCTACGAGC GGCTCGGCTT CACCGTCACC GCGGACGTCG AGGTGCCCGA AGGACCGCGC ACCTGGTGCA
TGACCCGCAA GCCCGGTGCC TGAAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTTT
ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAACT CATCAATGTA TCTTAATAAC TTCGTATAAT
GTATGCTATA CGAAGTTAT



OTI Disclaimer:	These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
RefSeq:	NM_020386 , NM_001366112
UniProt ID:	Q9HDD0
Synonyms:	A-CI; H-REV107; HRASLS1; HRSL1; HSD28
Summary:	Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:21880860, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:21880860, PubMed:22825852, PubMed:27623847). Shows O-acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:21880860). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE) which serves as precursor for N-acylethanolamines (NAEs) (PubMed:21880860, PubMed:22825852, PubMed:27623847).[UniProtKB/Swiss-Prot Function]

Product images:

